These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31600029)

  • 1. Comparing Changes in Controlled Substance Prescribing Trends by Provider Type.
    Meadows AL; Strickland JC; Qalbani S; Conner KL; Su A; Rush CR
    Am J Addict; 2020 Jan; 29(1):35-42. PubMed ID: 31600029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mandatory Review of Prescription Drug Monitoring Program Before Issuance of a Controlled Substance Results in Overall Reduction of Prescriptions Including Opioids and Benzodiazepines.
    Manders L; Abd-Elsayed A
    Pain Physician; 2020 Jun; 23(3):299-304. PubMed ID: 32517396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.
    Lin HC; Wang Z; Boyd C; Simoni-Wastila L; Buu A
    Addict Behav; 2018 Jan; 76():348-354. PubMed ID: 28898808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription Drug Monitoring Programs Produce a Limited Impact on Painkiller Prescribing in Medicare Part D.
    Yarbrough CR
    Health Serv Res; 2018 Apr; 53(2):671-689. PubMed ID: 28101955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid Prescribing Behaviors - Prescription Behavior Surveillance System, 11 States, 2010-2016.
    Strickler GK; Kreiner PW; Halpin JF; Doyle E; Paulozzi LJ
    MMWR Surveill Summ; 2020 Jan; 69(1):1-14. PubMed ID: 31999681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State variation in opioid and benzodiazepine prescriptions between independent and nonindependent advanced practice registered nurse prescribing states.
    Schirle L; McCabe BE
    Nurs Outlook; 2016; 64(1):86-93. PubMed ID: 26712387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary care providers' prescribing practices of opioid controlled substances.
    Shields LB; Nasraty S; Bell AD; Vinayakan AN; Gudibanda RS; Hester ST; Honaker JT
    J Opioid Manag; 2016; 12(6):397-403. PubMed ID: 28059432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use.
    Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM
    J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between prescription drug monitoring programs use mandates and prescription stimulants received by Medicaid enrollees.
    Gunadi C; Shi Y
    Drug Alcohol Rev; 2023 Nov; 42(7):1658-1666. PubMed ID: 37946605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP).
    Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC
    Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mandatory prescription drug monitoring programs and overlapping prescriptions of opioids and benzodiazepines: Evidence from Kentucky.
    Nguyen T; Meille G; Buchmueller T
    Drug Alcohol Depend; 2023 Feb; 243():109759. PubMed ID: 36621199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid Prescribing Patterns and Patient Outcomes by Prescriber Type in the Oregon Prescription Drug Monitoring Program.
    Fink PB; Deyo RA; Hallvik SE; Hildebran C
    Pain Med; 2018 Dec; 19(12):2481-2486. PubMed ID: 29155988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians.
    Bao Y; Pan Y; Taylor A; Radakrishnan S; Luo F; Pincus HA; Schackman BR
    Health Aff (Millwood); 2016 Jun; 35(6):1045-51. PubMed ID: 27269021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.
    Strickler GK; Zhang K; Halpin JF; Bohnert ASB; Baldwin GT; Kreiner PW
    Drug Alcohol Depend; 2019 Jun; 199():1-9. PubMed ID: 30954863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations in prescription drug monitoring program use by prescriber specialty.
    Sun BC; Lupulescu-Mann N; Charlesworth CJ; Kim H; Hartung DM; Deyo RA; John McConnell K
    J Subst Abuse Treat; 2018 Nov; 94():35-40. PubMed ID: 30243415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Doctor and pharmacy shopping": A fading signal for prescription opioid use monitoring?
    Delcher C; Harris DR; Park C; Strickler GK; Talbert J; Freeman PR
    Drug Alcohol Depend; 2021 Apr; 221():108618. PubMed ID: 33677354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provider Prescription Drug Monitoring Program Utilization and Self-Auditing-A Pilot Study.
    Brown WC; Whitted K
    J Dr Nurs Pract; 2020 Jul; 13(2):142-147. PubMed ID: 32817503
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.